Stematix enters into 10-year exclusive agreement with Laboratorios Bagó SA

Stematix, Inc. (Houston, USA), a regenerative medicine provider positioned to accelerate safe and effective global use of stem cell therapies, announced today that it entered into a 10-year exclusive agreement with Laboratorios Bagó (Buenos Aires, Argentina), a leading Argentine medical products company. Under terms of the Agreement, Laboratorios Bagó will distribute a variety of Stematix orthopedic and cellular products for use in regenerative and related medical treatments. The terms of the contract were not disclosed, but the contract also provides the option of additional forms of joint collaboration in clinical trials and treatments.

Regenerative medicine is already being used in therapy around the world. Already, many indications have been treated using cells from bone marrow and umbilical cord cells. In order to provide more widespread world-class regenerative medicine therapy, Stematix has established a model for fast-tracking therapies using cell sources from bone marrow to other allogeneic (cross-patient) sources of stem cells, such as umbilical cord and placental cells. As part of this model, Stematix is in-licensing and partnering with strong local partners in several key regions of the world, as well as developing its own, new technologies.

Stematix, Inc., is a sponsor of the 5^th Annual Stem Cell Summit (www.stemcellsummmit.com) in New York City on February 16 and will be a presenter at that conference.